Mielóma multiplex: vizsgálatok itt: Kína
204 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleMRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07106736 - 1/2. fázisTaking peopleA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Where
- Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
- Életkor
- 18 év and over
- People
- 246 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00 - 2. fázisNot yet taking people in KínaCM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 24
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07830485 - 3. fázisNot yet taking people in KínaA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Beijing, Shanghai
- Életkor
- 18 év to 130 év
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637 - 1. fázisTaking peopleA Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Where
- Hangzhou, Tianjin
- Életkor
- 18 év and over
- People
- 127 worldwide
- Run by
- AbbVie
See details and how to joinNCT07409246 - 2. fázisCsak meghívásosInternational Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- Sanofi
See details and how to joinNCT05669989 - 3. fázisNot yet taking people in KínaA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Where
- Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing, Ningbo, Shanghai, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Zhengzhou
- Életkor
- 18 év and over
- People
- 508 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391657 - 1. fázisTaking peopleGPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 50
- Run by
- Peking University First Hospital
See details and how to joinNCT07660939 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Shenzhen, Tianjin, Tijian, Wenzhou, Wuhan, Xi'an
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07518186 - 1. fázisTaking peopleA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Where
- Baoding, Beijing, Bengbu, Cangzhou, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Ganzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Hohhot, Jinan, Jining, Liuzhou, Luoyang, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xinxiang, Xuzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 258 worldwide
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT07477587 - 2. fázisTaking peopleCM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
- Where
- Tianjin
- Életkor
- 18 év to 80 év
- People
- 26
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07585760 - 3. fázisTaking peopleA Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 255
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07623798 - 1/2. fázisTaking peopleA Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
- Where
- Shanghai, Suzhou
- Életkor
- 18 év and over
- People
- 68
- Run by
- UCARsgen Biotech Limited
See details and how to joinNCT07760454 - No phaseTaking peopleA Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
- Where
- Beijing
- People
- 2000
- Run by
- Peking University First Hospital
See details and how to joinNCT05283993 - 1. fázisTaking peopleSafety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- Where
- Beijing, Tianjin
- Életkor
- 18 év to 75 év
- People
- 9
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT07620275 - 3. fázisTaking peopleMobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
- Where
- Beijing, Harbin
- Életkor
- 18 év to 78 év
- People
- 60
- Run by
- Guangzhou Gloria Biosciences Co., Ltd.
See details and how to joinNCT06514508 - 2. fázisNot yet taking people in KínaHP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 20
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07811986 - Korai 1. fázisTaking peopleA Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
- Where
- Beijing, Chongqing, Shanghai, Zhengzhou
- Életkor
- 18 év to 80 év
- People
- 30
- Run by
- Suzhou Immunofoco Biotechnology Co., Ltd
See details and how to joinNCT07493135 - 1/2. fázisTaking peopleA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Where
- Shanghai, Suzhou
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00 - 1. fázisTaking peopleStudy of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Beijing, Fuzhou, Guangzhou, Hanzhou, Nanjing, Tianjin, Zhengzhou
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Jiangsu Simcere Pharmaceutical Co., Ltd.
See details and how to joinNCT06375044 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Beijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00 - No phaseTaking peopleCD38 Targeted -PET/ CT for Multiple Myeloma
- Where
- Guilin
- Életkor
- 18 év and over
- People
- 100
- Run by
- Guilin Medical University, China
See details and how to joinNCT07782944 - 1/2. fázisTaking peopleA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 123 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00 - 2. fázisNot yet taking people in KínaA Open-Label Phase in Participants With Multiple Myeloma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 120
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07764861 - No phaseTaking peopleLow-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
- Where
- Hainan
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
See details and how to joinNCT07763054